Choose a language and wait for the translated text.
Shots:
Inocras and AimedBio have partnered to integrate Inocras’ whole-genome sequencing (WGS) platform into AimedBio’s ADC clinical programs, alongside AimedBio’s strategic equity investment in Inocras
As per the deal, AimedBio will use Inocras’ WGS, cancer intelligence platform, & multi-omics analyses across its ADC trials to enable biomarker discovery, patient selection, and novel target identification
The collaboration aims to accelerate clinical development, enable precision drug discovery, and explore global commercial opportunities by integrating AimedBio’s drug screening with Inocras’ diagnostic platform
Ref: Businesswire |  Image: Inocras & AimedBio | Press Release
Related News: Junshi Biosciences Licenses Roconkibart to Fosun Wanbang in Greater China
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Inocras and AimedBio Collaborate on Precision Oncology and ADC Development appeared first on PharmaShots.
